U.S. markets open in 1 hour 15 minutes
  • S&P Futures

    4,275.00
    -32.75 (-0.76%)
     
  • Dow Futures

    33,929.00
    -189.00 (-0.55%)
     
  • Nasdaq Futures

    13,537.75
    -120.50 (-0.88%)
     
  • Russell 2000 Futures

    2,006.40
    -16.90 (-0.84%)
     
  • Crude Oil

    86.45
    -0.08 (-0.09%)
     
  • Gold

    1,784.10
    -5.60 (-0.31%)
     
  • Silver

    19.78
    -0.30 (-1.49%)
     
  • EUR/USD

    1.0166
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    2.8240
    0.0000 (0.00%)
     
  • Vix

    20.53
    +0.58 (+2.91%)
     
  • GBP/USD

    1.2072
    -0.0023 (-0.19%)
     
  • USD/JPY

    135.1360
    +0.9210 (+0.69%)
     
  • BTC-USD

    23,757.75
    -304.90 (-1.27%)
     
  • CMC Crypto 200

    565.76
    -6.16 (-1.08%)
     
  • FTSE 100

    7,509.35
    -26.71 (-0.35%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Celldex to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November:

  • Guggenheim 3rd Annual Healthcare Talks Neuro/Immunology Conference on Tuesday, November 16, 2021 at 10:20 a.m. ET

  • Jefferies London Healthcare Conference available on-demand beginning Thursday, November 18, 2021 at 3:00 a.m. ET / 8:00 a.m. GMT

  • Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 8:25 a.m. ET

Webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for 30 days following the events.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com